Dapagliflozin Patient Satisfaction Survey

Direct to Patient Survey to Examine Treatment Satisfaction and Experience With Dapagliflozin Compared to Sulfonylureas

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02805283

Enrollment

653

Registered

2016-06-20

Start date

2016-06-22

Completion date

2018-10-29

Last updated

2019-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes Mellitus, Type 2

Brief summary

The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus

Detailed description

This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification. * Evidence of T2D diagnosis. * Age ≥18 as of the drug index date. * 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date. * Self-reported T2D diagnosis during the patient interview.

Exclusion criteria

* Patients with evidence of type 1 diabetes mellitus and unknown type * Patients who are pregnant

Design outcomes

Primary

Measure	Time frame	Description
Condition-specific treatment satisfaction	2 weeks	Condition-specific treatment satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)

Secondary

Measure	Time frame	Description
Medical Outcomes Study (MOS) Short Form Health Survey SF-12 or SF-36	4 weeks	MOS Short Form Health Survey SF-12 or SF-36
Morisky Medication Adherence Scale	1 month	Medication adherence
Hypoglycemia Fear Survey	4 weeks	Fear of hypoglycemia (HFS)
Self-reported body weight	1 month	Self-reported body weight

Countries

United States

Outcome results